Business Context and Reporting Period
This Form 8-K filing by Nanoviricides, Inc. covers the event date of June 24, 2013. The report details a corporate governance change involving the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Dr. Mukund S. Kulkarni as an independent member of the Board of Directors. Dr. Kulkarni brings extensive experience in finance and economics, including serving as Chancellor of Penn State Harrisburg since 2010 and holding various academic leadership roles since 1985.
Compensatory Arrangements and Outlook
As part of his appointment, the company has agreed to compensate Dr. Kulkarni an annual amount of $30,000, payable on a quarterly basis. The filing does not provide specific guidance, outlook, or discussion of risks beyond the standard disclosure of the director's appointment.
Investor Verification Points
- Verify the effective date of Dr. Kulkarni's board membership (June 24, 2013).
- Confirm the annual compensation obligation of $30,000 for the new director.
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.